[(3,5-dimethylphenyl)methyl](methyl)amine | 148452-35-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(3,5-dimethylphenyl)methyl](methyl)amine
• 英文别名: 3,5-dimethyl-N-methylbenzylamine；N-methyl-N-(3,5-dimethylbenzyl)amine；(3,5-dimethyl-benzyl)-methyl-amine；1-(3,5-dimethylphenyl)-N-methylmethanamine
• CAS: 148452-35-1
• 化学式: C₁₀H₁₅N
• mdl: MFCD11204861
• 分子量: 149.236
• InChiKey: HHXARJLFDKHCCL-UHFFFAOYSA-N

物化性质

• 沸点：
  215.1±9.0 °C(Predicted)
• 密度：
  0.912±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [(3,5-dimethylphenyl)methyl](methyl)amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 35.0h， 生成 2-(4-Methyl-piperazin-1-yl)-5-o-tolyl-pyrimidine-4-carboxylic acid (3,5-dimethyl-benzyl)-methyl-amide
  参考文献：
  名称：

  5-phenyl-pyrimidine derivatives

  摘要：

  描述了一般公式的化合物：其中R1是氢或卤素；R2是氢、卤素、低烷基或低烷氧基；R3是卤素、三氟甲基、低烷氧基或低烷基；R4/R4′分别是氢或低烷基；R5是低烷基、低烷氧基、氨基、羟基、羟基-低烷基、—(CH2)n-哌嗪基，可选地被低烷基取代，—(CH2)n-吗啉基，—(CH2)n+1-咪唑基，—O—(CH2)n+1-吗啉基，—O—(CH2)n+1-哌啶基，低烷基硫基，低烷基磺酰基，苄氨基，—NH—(CH2)n+1N(R4″)2，—(CH2)n—NH—(CH2)n+1N(R4″)2，—(CH2)n+1N(R4″)2，或—O—(CH2)n+1N(R4″)2，其中R4″是氢或低烷基；R6是氢；R2和R6或R1和R6可以共同为—CH2CH—CH2CH—，其中R2和R6或R1和R6，分别与它们连接的两个碳环原子形成融合环，但R1的n为1；n独立地为0-2；X为—C(O)N(R4″)—或—N(R4″)C(O)—；以及其药学上可接受的酸盐。

  公开号：

  US06756380B1
• 作为产物：
  描述：

  在 盐酸 作用下， 反应 0.5h， 生成 [(3,5-dimethylphenyl)methyl](methyl)amine
  参考文献：
  名称：

  L-色氨酸衍生的NK1拮抗剂的合成和生物学评估。

  摘要：

  N-乙酰基-L-色氨酸苄酯的3,5-双（三氟甲基）苄基酯（3）来源于筛选铅N-乙基-L-色氨酸苄酯，已被用作鉴定高-亲和性物质P受体拮抗剂具有改善的体内活性。将酯部分改变为酰胺或醚会导致结合亲和力的显着损失，但是转化为酮可提供与当量酯相当的亲和力的化合物。关键中间体氨基酮15的同手性合成得以开发，可以大规模制备。从该中间体中制备了一系列含胺的酰氨基衍生物，并在吗啉基丁酰胺161中对亲和力进行了优化，该衍生物对人NK1受体的IC50为0.17 nM。除了改善亲和力 氨基还为许多这些衍生物提供了水溶性。在体内进行测试时，发现奎尼丁衍生物L-737,488（16i）是豚鼠中P物质诱导的皮肤外渗的口服活性抑制剂（ID50 = 1.8 mg / kg）。

  DOI：

  10.1021/jm00006a012

文献信息

• [EN] NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA NEUROKININE 1
  申请人：LEO PHARMA AS

  公开号：WO2013124286A1

  公开（公告）日：2013-08-29

  The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hydroxy or NR8R9; R4 is hydrogen or oxo; R5 and R6 are independently hydrogen, hydroxy, NR8R9, C( =O)R7, C( =O)OR7, C( =O)NR8R9, C1-4 alkyl, wherein said C1-4 alkyl is optionally substituted with hydroxy, NR8R9 or a 5- or 6-membered heterocyclic ring, wherein said 5- or 6-membered heterocyclic ring is optionally substituted with C1-4 alkyl or C(=O)R7; or R5 and R6, together with the carbon atom to which they are attached, form =CH2 or a 5- or 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with C1-4 alkyl; R7 is hydrogen or C1-4 alkyl; R8 and R9 are independently hydrogen or C1-4 alkyl, or R8 and R9, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic ring, or a pharmaceutically acceptable salt or solvate thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating or ameliorating pruritic dermal diseases or conditions with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种根据公式（A）的化合物，其中n为1或2；R1和R2独立为氢，C1-4烷基，C1-4卤代烷基，C1-4烷氧基，CD3或卤素；R3为氢，C(=O)OR7或C1-4烷基，可选地被羟基或NR8R9取代；R4为氢或氧代；R5和R6独立为氢，羟基，NR8R9，C(=O)R7，C(=O)OR7，C(=O)NR8R9，C1-4烷基，其中所述C1-4烷基可选地被羟基，NR8R9或5-或6-成员的杂环环取代，其中所述5-或6-成员的杂环环可选地被C1-4烷基或C(=O)R7取代；或R5和R6与它们所连接的碳原子一起形成=CH2或5-或6-成员的杂环烷基，其中所述杂环烷基可选地被C1-4烷基取代；R7为氢或C1-4烷基；R8和R9独立为氢或C1-4烷基，或R8和R9与它们所连接的氮原子一起形成一个5-或6-成员的杂环环，或其药用可接受的盐或溶剂化物。本发明进一步涉及用于制备所述化合物的中间体，所述化合物用于治疗，包含所述化合物的药物组合物，使用所述化合物治疗或改善瘙痒性皮肤病或状况的方法，以及所述化合物在药物制造中的用途。
• Indanyl-piperazine compounds
  申请人：De Nanteuil Guillaume

  公开号：US20060223830A1

  公开（公告）日：2006-10-05

  A compound selected from those of formula (I): wherein: R 3 represents a hydrogen atom, and R 1 and R 2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, or R 1 represents a hydrogen atom, and R 2 and R 3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH 2 ) m —O-Ak-, —(CH 2 ) m —NR 4 -Ak-, —(CO)—NR 4 -Ak- and —(CH 2 ) m —NR 4 -(CO)—, m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R 4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK 1 antagonist.

  从公式（I）中选择的化合物：其中：R3代表氢原子，R1和R2与携带它们的碳原子一起形成苯、萘或喹啉环结构，每个环结构可选择地被取代，或R1代表氢原子，R2和R3与携带它们的碳原子一起形成苯、萘或喹啉环结构，每个环结构可选择地被取代，n代表1或2，-X-代表从-(CH2)m-O-Ak-、-(CH2)m-NR4-Ak-、-(CO)-NR4-Ak-和-(CH2)m-NR4-(CO)-中选择的基团，m代表1到6之间的整数，Ak代表可选择地取代的烷基链，R4代表氢原子或烷基基团，Ar代表芳基或杂环芳基基团，它的对映异构体、顺反异构体和与药用酸形成的加合物。含有这些化合物的医药产品在治疗需要血清素再摄取抑制剂和/或NK1拮抗剂的病症中有用。
• 2,4,5,-trisubstituted pyrimidine derivatives
  申请人：——

  公开号：US20020099207A1

  公开（公告）日：2002-07-25

  The invention relates to compounds of the formula 1 wherein R 1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, —S-lower alkyl, —S(O) 2 -lower alkyl, —N(R)—(CH 2 ) n —N(R) 2 , —O—(CH 2 ) n —N(R) 2 , —N(R) 2 , or a cyclic tertiary amine of the group 2 which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker —O(CH 2 ) n —; R 2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 3 /R 3 ′ is, independently from each other, hydrogen or lower alkyl; R 4 is independently from each other halogen, trifluoromethyl or lower alkoxy; R 5 is hydrogen or lower alkyl; R is, independently from each other, hydrogen or lower alkyl; X is —C(O)N(R)— or —N(R)C(O)—; Y is —O—, —S—, —SO 2 —, - or —N(R)—; n is 1,2,3 or 4; and m is 0,1 or 2; or a pharmaceutically acceptable acid addition salt thereof. The compound of the invention has affintity to the NK1 receptor and is therefore suitable in the treatment of diseases related to this recepor.

  该发明涉及具有下列结构的化合物1： 其中 R1是较低的烷基、较低的烷氧基、吡啶基、嘧啶基、苯基、—S-较低的烷基、—S(O)2-较低的烷基、—N(R)—(CH2)n—N(R)2、—O—(CH2)n—N(R)2、—N(R)2或者2组的环状三级胺，该组可能包含一个额外的异原子，选自N、O或S，且该组可以通过连接基团—O(CH2)n—与嘧啶环连接； R2是氢、较低的烷基、较低的烷氧基、卤素或三氟甲基； R3/R3'分别是氢或较低的烷基； R4是独立的卤素、三氟甲基或较低的烷氧基； R5是氢或较低的烷基； R是独立的氢或较低的烷基； X是—C(O)N(R)—或—N(R)C(O)—； Y是—O—、—S—、—SO2—或—N(R)—； n是1、2、3或4； m是0、1或2； 或其药学上可接受的酸盐。该化合物具有对NK1受体的亲和力，因此适用于治疗与该受体相关的疾病。
• Intramolecular borylation reaction catalyzed by Lewis acid: preparation of 1H-2,1-benzazaborole derivatives
  作者：Alexander M. Genaev、Georgii E. Salnikov、Vyacheslav G. Shubin、Sandor M. Nagy

  DOI：10.1039/b003999n

  日期：——

  It has been found that 1H-2,1-benzazaboroles can be prepared by the interaction of substituted benzylaminochloroboranes with Al2Cl6 in CH2Cl2 at 0 °C, the 13C NMR spectroscopy data obtained being in favour of an electrophilic substitution mechanism involving formation of cationic complexes as reactive intermediates.

  已经发现 1H-2,1-苯并氮杂硼烷可以通过取代的苄基氨基氯硼烷与 Al2Cl6 在 CH2Cl2 中在 0°C 的相互作用来制备，获得的 13C NMR 光谱数据有利于亲电子取代机制，涉及形成阳离子配合物反应中间体。
• Tachykinin receptor antagonists
  申请人：Amegadzie Kudzovi Albert

  公开号：US20060160794A1

  公开（公告）日：2006-07-20

  The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

  本发明涉及公式(I)或其药学上可接受的盐的选择性NK-1受体拮抗剂，用于治疗与过量Tachykinins相关的疾病。